Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure

American Journal of Cardiology

Volumn 83, Issue 8, 1999, Pages 1274-1277

  Kanda, Munetake ^a   Yasuda, Satoshi ^a   Goto, Yoichi ^a   Sumida, Hitoshi ^a   Baba, Takeshi ^a   Noguchi, Teruo ^a   Nonogi, Hiroshi ^a  

^a Div of Cardiology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; DRUG SCREENING; FEMALE; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

EID: 0033560884     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00073-9     Document Type: Article

References (13)

1. Cody R.J. Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure. Am J Cardiol. 63:1989;31A-34A.
2. Brenner B.M., Rector F.C. Jr. The Kidney. 1991;W.B. Saunders Co, Philadelphia, PA.
3. Klein N.A., Siskind S.J., Frishman W.H., Sonnenblick E.H., LeJemtel T.H. Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. Am J Cardiol. 48:1981;170-175.
4. Maskin C.S., Sinoway L., Chadwick B., Sonnenblick E.H., LeJemtel T.H. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation. 67:1983;1065-1070.
5. Takaoka H., Takeuchi M., Odake M., Hayashi Y., Mori M., Hata K., Yokoyama M. Comparison of the effects of atrial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased heart. J Am Coll Cardiol. 22:1993;598-606.
6. Cody R.J., Ljungman S., Covit A.B., Kubo S.H., Sealey J.E., Pondolfino K., Clark M., James G., Laragh J.H. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 34:1988;361-373.
7. Anand I.S., Ferrari R., Kalra G.S. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 80:1989;299-305.
8. Liang C.-S., Thomas A., Imai N., Stone C.K., Kawashima S., Hood W.B. Jr. Effects of milrinone on systemic hemodynamics and regional circulation in dogs with congestive heart failure comparisons with dobutamine . J Cardiovasc Pharmacol. 10:1987;509-516.
9. Strain J., Grose R., Markin C.S., LeJemtel T.H. Effects of a new cardiotonic agent, MDL 17,043, on myocardial contractility and left ventricular performance in congestive heart failure. Am Heart J. 110:1985;91-96.
10. Smith N.A., Kates R.E., Lebsack C., Ruder M., Mead H., Bekele T., Okerholm R.A., Rubin G.M., Winkle R.A. Clinical pharmacology of intravenous enoximone pharmacodynamics and pharmacokinetics in patients with heart failure . Am Heart J. 122:1991;755-762.
11. LeJemtel T.H., Maskin C.S., Mancini D., Sinoway L., Feld H., Chadwick B. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation. 72:1985;364-369.
12. Dworkin L.D., Ichikawa I., Brenner B.M. Hormonal modulation of glomerular function. Am J Physiol. 244:1983;F95-F104.
13. Cody RJ, Kubo SH, MIL 0.5 Covit AB, Muller FB, Rutman H, Leonard D, Laragh JH, Feldschuh J, Preibisz J. Regional blood flow and neurohormonal responses to milrinone in congestive heart failure. Clin Pharmacol Ther 1986;39:128-135.